Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Papillary renal cell carcinoma, sporadic 1Melanoma 1Lung Neoplasms 1Hereditary leiomyomatosis and renal cell cancer 1Healthy Volunteers 1Fallopian Tube Mucinous Adenocarcinoma 1Ependymoma 1Craniopharyngioma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 15Cisplatin 9Paclitaxel 6Nivolumab 5Fluorouracil 4Carboplatin 4atezolizumab 3Sunitinib 3Specimen Handling 3Radiotherapy 3Doxorubicin 3pegfilgrastim 2eribulin 2cabozantinib 2avelumab 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Ifosfamide 2Docetaxel 2CTLA-4 Antigen 2Biopsy 2vinflunine 1vandetanib 1tocilizumab 1tamibarotene 1rucaparib 1rubitecan 1romidepsin 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urethral Neoplasms × Contrast Media × Clear all
NCT03237780 2026-05-13

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
72 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡